FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to pharmaceutics, namely to a pharmaceutical substance for preparing a medicinal agent for treating infected wounds. Substance is characterized by the inclusion of an effective amount of the active ingredients miramistin and chitosan, as well as acetic acid as an adjuvant and water with the following ingredients content, wt. %: Miramistin - 0.05, Chitosan - 1.0, Acetic acid - 0.6, Purified water - up to 100.0. Method of producing a pharmaceutical substance is characterized by the fact that chitosan is mixed with 0.5 % acetic acid solution, continuously mixed and poured water to obtain a suspension, mixed until complete dissolution of chitosan and left to stand until a gel-like solution is obtained, then the antimicrobial preparation Miramistin is immobilized on chitosan at room temperature at a weight ratio of chitosan to miramistin 20:1 and is obtained by lyophilisation at -40 °C chitosan and miramistin substance in the form of a spongy cancellous mass, wherein water is removed from frozen substance by sublimation of ice.
EFFECT: invention enables to obtain a biologically active compound: a chitosan complex with an antimicrobial preparation miramistin (CCM), as well as a wider range of wound healing and antimicrobial agents.
1 cl, 7 dwg, 3 ex
Title | Year | Author | Number |
---|---|---|---|
COMBINED COMPOSITION FOR TREATING INFECTED WOUNDS OF VARIOUS ORIGINS | 2018 |
|
RU2691144C1 |
PHARMACEUTICAL SUBSTANCE FOR TREATING INFECTED WOUNDS OF VARIOUS ORIGINS | 2018 |
|
RU2687102C1 |
PHARMACEUTICAL COMBINED COMPOSITION FOR LOCAL AND EXTERNAL USE ON BASIS OF DIOXIDINE | 2016 |
|
RU2667974C2 |
PHARMACEUTICAL COMBINED COMPOSITION FOR LOCAL AND EXTERNAL USE ON BASIS OF BACTERIOLYTIC AND PROTEOLYTIC COMPLEX OF ENZYMES | 2016 |
|
RU2655808C2 |
PHARMACEUTICAL COMBINED COMPOSITION FOR THE TREATMENT OF PURULENT WOUNDS ON THE BASIS OF FLUOROQUINOLONS (OPTIONS) | 2016 |
|
RU2682171C2 |
METHOD OF PRODUCING BIOCOMPOSITE WITH REGENERATIVE PROPERTIES BASED ON HYDROGEL OF BACTERIAL CELLULOSE | 2019 |
|
RU2733137C1 |
PHARMACEUTICAL COMPOSITION CONTAINING ENZYME RIBONUCLEASE AND GLYCYRRHIZIC ACID OR SALTS THEREOF: AMMONIUM OR DIPOTASSIUM OR TRISODIUM GLYCYRRHIZINATE | 2012 |
|
RU2504396C1 |
PHARMACEUTICAL COMPOSITION CONTAINING LYSINE, PROLINE AND TRITERPENIC ACID DERIVATIVES FOR TREATING AND PREVENTING VIRAL INFECTIONS CAUSED BY RNA- AND DNA-CONTAINING VIRUSES, SUCH AS: INFLUENZA, HERPES, HERPES ZOSTER, HUMAN PAPILLOMA, ADENOVIRUSES, AS WELL AS BACTERIAL INFECTIONS CAUSED BY GRAM-POSITIVE AND GRAM-NEGATIVE MICROORGANISMS | 2013 |
|
RU2535052C1 |
OPHTHALMIC OINTMENT FORMULATION AND METHOD FOR PREPARING SAME | 2012 |
|
RU2531937C2 |
USE OF BENZYLDIMETHYL[3-(STEARINOYLAMINO)PROPYL] AMMONIUM CHLORIDE AS AN ANTIBACTERIAL AND/OR ANTISEPTIC AGENT AND METHOD OF ITS OBTAINING | 2022 |
|
RU2808635C1 |
Authors
Dates
2019-08-21—Published
2018-04-28—Filed